Stockscreener 앱 받기
103.67
1.89%
-2.00
시간 외 거래:
104.49
0.82
+0.79%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Globe and Mail
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Motley Fool
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Is Axsome Therapeutics Stock Worth The Risk? A Comprehensive Analysis - Barchart.com
Fibromyalgia Treatment Market to Reach $3.88 Billion by 2033 | - openPR.com
Axsome in $570 million loan and revolving credit facility with Blackstone - The Pharma Letter
Frontier Capital Management Co. LLC Has $4.47 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Q2 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
Transcript : Axsome Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
William Blair Analysts Boost Earnings Estimates for AXSM - MarketBeat
Cubist Systematic Strategies LLC Invests $9.89 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Fairmount Funds Management LLC Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Major Depressive Disorder Market Growth to Accelerate - openPR.com
Axsome Therapeutics enters $570M term loan, credit facility with Blackstone - MSN
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Axsome Therapeutics Enters $570 Million Credit Deal With Blackstone - marketscreener.com
Axsome Therapeutics (AXSM) Secures $570 Million Credit Facility - GuruFocus
Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - Nasdaq
Axsome Therapeutics Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - marketscreener.com
3 Monster Stocks in the Making - aol.com
Axsome secures $570 million credit facility from Blackstone - Investing.com
Axsome secures $570 million credit facility from Blackstone By Investing.com - Investing.com Nigeria
Axsome Therapeutics Secures $570 Million Financing Facility with Blackstone, Retires Previous Loan - Nasdaq
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - The Manila Times
BNP Paribas Financial Markets Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Northern Trust Corp - MarketBeat
HC Wainwright Issues Negative Outlook for AXSM Earnings - MarketBeat
Price T Rowe Associates Inc. MD Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Has Bullish Forecast for AXSM FY2028 Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $180.00 at HC Wainwright - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Schonfeld Strategic Advisors LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $162.00 Price Target at Robert W. Baird - MarketBeat
Balyasny Asset Management L.P. Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% Following Better-Than-Expected Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Quarterly Earnings Results, Beats Estimates By $0.46 EPS - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
BVF Inc. IL Has $117.44 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FY2025 EPS Estimates for AXSM Lifted by Cantor Fitzgerald - MarketBeat
Axsome Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Alethea Capital Management LLC Has $62.13 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 14.2% in April - MarketBeat
Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025 - MSN
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - Yahoo Finance
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
0.15%
자본화:
|
볼륨(24시간):